Business
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 - September 5. RLYB116 is a novel, potentially long-acting subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases.\n\n\nDetails of the poster presentation are as follows:\n\n\n\nTitle: Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody® molecule linked to an Albumod® albumin binding domain\n\n\n\nPresenting Author: Eric Watsky, M.D., Rallybio\n\n\n\nAbstract Number: 36\n\n\n\nPoster Session Date and Time: September 3, 2023, from 14:30 - 16:30 (2:30 p.m. - 4:30 p.m. ET)\n\n\n\nAdditional information about the ICW 2023 Congress is available at: https://icw2023newcastle.co.uk/.\n\n\nAbout Rallybio\n\n\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.\n\n\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press releas...